Adma Biologics (ADMA) Non-Current Debt (2012 - 2026)
Adma Biologics' (ADMA) quarterly Non-Current Debt came in at $69.3 million in Q4 2025, down 4.16% YoY from $72.3 million in Q4 2024, and down 1.08% on a QoQ basis from $70.1 million in Q3 2025.
Adma Biologics (ADMA) Non-Current Debt (2012 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Non-Current Debt data on file, last reported at $69.3 million in Q4 2025.
- Quarterly Non-Current Debt fell 4.16% year-over-year to $69.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $69.3 million (down 4.16% YoY) and the FY2025 annual result came in at $69.3 million, down 4.16% from the prior year.
- Non-Current Debt declined to $69.3 million in Q4 2025, from $70.1 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $144.3 million in Q1 2023 to a low of $69.3 million in Q4 2025.
- A 5-year average of $110.9 million and a median of $116.0 million in 2023 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt jumped 50.56% — and 2024, when it slumped 44.61%.
- Tracing ADMA's Non-Current Debt over 5 years: stood at $94.9 million in 2021, then jumped by 50.56% to $142.8 million in 2022, then declined by 8.57% to $130.6 million in 2023, then tumbled by 44.61% to $72.3 million in 2024, then fell by 4.16% to $69.3 million in 2025.
- The last three Non-Current Debt figures came in at $69.3 million (Q4 2025), $70.1 million (Q3 2025), and $73.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 192.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 192.84 Mn |
| Dec 31, 2025 | 69.33 Mn |
| Sep 30, 2025 | 70.08 Mn |
| Jun 30, 2025 | 73.40 Mn |
| Mar 31, 2025 | 72.53 Mn |
| Dec 31, 2024 | 72.34 Mn |
| Sep 30, 2024 | 101.33 Mn |
| Jun 30, 2024 | 131.07 Mn |
| Mar 31, 2024 | 130.85 Mn |
| Dec 31, 2023 | 130.59 Mn |
| Sep 30, 2023 | 142.03 Mn |
| Jun 30, 2023 | 140.31 Mn |
| Mar 31, 2023 | 144.30 Mn |
| Dec 31, 2022 | 142.83 Mn |
| Sep 30, 2022 | 141.37 Mn |
| Jun 30, 2022 | 139.81 Mn |
| Mar 31, 2022 | 138.42 Mn |
| Dec 31, 2021 | 94.87 Mn |
| Sep 30, 2021 | 94.36 Mn |
| Jun 30, 2021 | 93.88 Mn |